---
id: 131
title: SARS-CoV-2 (COVID-19) Management
category: organisms
subcategory: viruses
tags: [COVID-19, SARS-CoV-2, paxlovid, remdesivir, dexamethasone, antivirals]
difficulty: medium
---

## Question

How is COVID-19 managed by severity? Use the **"Paxlovid for Outpatient High-Risk, Remdesivir + Dexamethasone for Severe"** framework.

## Answer

### **COVID-19 Treatment by Severity:**

| Severity | Oxygen Requirement | Treatment |
|----------|-------------------|-----------|
| **Mild-Moderate (Outpatient, High-Risk)** | None | **Nirmatrelvir-ritonavir (Paxlovid) 300/100mg PO BID × 5 days** (within 5 days of symptom onset) |
| **Severe (Hospitalized, Not Critical)** | Low-flow O2 | **Remdesivir 200mg IV × 1 → 100mg daily × 5-10 days** + **dexamethasone 6mg IV/PO daily** |
| **Critical (ICU, High-Flow O2/Ventilated)** | High-flow O2, NIV, mechanical ventilation | **Remdesivir** + **dexamethasone 6mg daily** + **tocilizumab 8 mg/kg IV × 1** (if progressing) |

### **Outpatient Antiviral Therapy (High-Risk Patients):**

**First-Line: Nirmatrelvir-Ritonavir (Paxlovid)**
- **Dosing:** 300mg nirmatrelvir + 100mg ritonavir PO BID × 5 days
- **Start:** Within **5 days** of symptom onset
- **Indication:** High-risk for progression (age ≥65, immunocompromised, chronic conditions)
- **Contraindications:** Severe renal/hepatic impairment, **significant drug interactions** (ritonavir is strong CYP3A4 inhibitor)
- **Rebound:** 10-15% experience symptom/viral rebound after completion (usually mild, self-limited)

**Alternative: Remdesivir (Outpatient Formulation)**
- **Dosing:** 200mg IV × 1 → 100mg IV daily × 3 days (total 3 days)
- **Indication:** If paxlovid contraindicated or unavailable
- **Requires:** IV infusion (outpatient infusion center)

**Alternative: Molnupiravir**
- **Dosing:** 800mg PO BID × 5 days
- **Less effective** than paxlovid (~30% vs ~90% reduction in hospitalization)
- **Teratogenic** (contraindicated in pregnancy)

### **Hospitalized Patients:**

**Remdesivir:**
- **Dosing:** 200mg IV × 1 → 100mg IV daily
- **Duration:** **5 days** (if improving) OR **10 days** (if not improving or immunocompromised)
- **Indication:** Hospitalized patients requiring oxygen
- **Benefit:** Reduces time to recovery, modest mortality benefit

**Dexamethasone:**
- **Dosing:** **6mg IV or PO daily × 10 days** (or until discharge)
- **Indication:** **Requiring supplemental oxygen** (do NOT use if not requiring O2)
- **Benefit:** **Mortality reduction** in severe/critical disease (35% relative risk reduction in ventilated patients)
- **Harm:** May worsen outcomes if given to patients NOT requiring oxygen

**Tocilizumab (IL-6 Inhibitor):**
- **Dosing:** 8 mg/kg IV × 1 dose (can repeat at 12-24h if needed)
- **Indication:** Hospitalized + requiring oxygen + **rapidly progressing** (↑O2 requirement or CRP >75 mg/L) + within 24-48h of admission
- **Benefit:** Reduced mortality, reduced mechanical ventilation
- **Timing:** Early in disease course (within 24-48h of ICU admission)

## Key Points

### **High-Risk Factors for Progression:**
- **Age ≥65 years**
- **Immunocompromised** (HIV, transplant, immunosuppressive therapy)
- **Chronic medical conditions:** Diabetes, CKD, cardiovascular disease, COPD, obesity (BMI ≥30)
- **Unvaccinated** or incompletely vaccinated

### **Drug Interactions (Paxlovid/Ritonavir):**
**Contraindicated:**
- **Alfuzosin**, **amiodarone**, **colchicine** (if renal/hepatic impairment)
- **Ergot derivatives**, **lovastatin**, **simvastatin**
- **Pimozide**, **ranolazine**, **sildenafil** (for pulmonary HTN)
- **St. John's Wort**, **rifampin**

**Require dose adjustment or holding:**
- **Statins** (hold atorvastatin/rosuvastatin during treatment)
- **Immunosuppressants** (tacrolimus, cyclosporine - reduce dose, monitor levels)
- **Anticoagulants** (rivaroxaban, apixaban - monitor closely)

### **Post-Acute Sequelae of COVID-19 (PASC / "Long COVID"):**
- **Definition:** Symptoms persisting **>4 weeks** after acute infection
- **Common symptoms:** Fatigue, dyspnea, cognitive impairment ("brain fog"), post-exertional malaise
- **Prevalence:** 10-30% of infected individuals
- **Management:** Supportive care, symptom-directed therapy, multidisciplinary approach
- **No proven treatments** (pacing, graded exercise may help selected patients)

### **Vaccination:**
- **Most effective prevention strategy**
- **Updated boosters** target circulating variants
- **Reduces:** Infection risk, severe disease, hospitalization, death, long COVID

### **Clinical Pearls:**
- **Outpatient high-risk:** Paxlovid 300/100mg PO BID × 5 days (within 5 days of symptoms)
- **Hospitalized + oxygen:** Remdesivir + dexamethasone 6mg daily
- **Critical/progressing:** Add tocilizumab (if within 24-48h of ICU admission)
- **Dexamethasone ONLY if requiring oxygen** (harm if not hypoxic)
- **Paxlovid drug interactions:** Check before prescribing (ritonavir = strong CYP3A4 inhibitor)
- **Rebound:** 10-15% after paxlovid (usually mild, self-limited)

## Sources

- [NIH COVID-19 Treatment Guidelines 2024]
- [IDSA: COVID-19 Guidelines 2024]

## Media

N/A
